Aridis Pharmaceuticals (ARDS) Stock Price, News & Analysis

Company Overview

Aridis Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on developing therapies for serious infectious diseases. The company used its proprietary antibody discovery and development technologies to create fully human monoclonal antibodies intended to target bacterial pathogens and toxins, with an emphasis on hospital-acquired and antibiotic-resistant infections.

Aridis’ leading program was suvratoxumab, also known as AR-301, an investigational monoclonal antibody designed to neutralize alpha toxin produced by Staphylococcus aureus. The company evaluated the therapy for use in patients with pneumonia, including ventilator-associated and hospital-acquired pneumonia. Its broader development portfolio included additional antibody candidates targeting infectious-disease pathogens and toxins.

Founded in 2003 and headquartered in San Jose, California, Aridis conducted research and clinical development activities in the United States and worked with international partners and clinical sites. The company was led by Vu Truong, Ph.D., who served as chief executive officer and was involved in the company’s scientific and corporate development.

Aridis Pharmaceuticals was historically listed on the Nasdaq under the symbol ARDS. Information about the company’s later corporate status and operations may differ from descriptions published during its period as an actively developing biotechnology company.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.05
• Volume: 10,000 shs
• Average Volume: 16,556 shs
• Market Capitalization: $5.33 thousand
• P/E Ratio: 0.00
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/10/2021
• Today: 9/24/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ARDS
• CIK: 1614067
• Web: www.aridispharma.com
• Phone: (408) 385-1742
• Fax: 408-960-3822
• Employees: 30
• Year Founded: 2003

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.00
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 53,321,000
• Free Float: 50,388,000
• Market Cap: $5.33 thousand
• Optionable: Not Optionable
• Beta: 49.95